Patents by Inventor Atsuya NAKAMURA

Atsuya NAKAMURA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210251902
    Abstract: Provided is a composition comprising delamanid particles for which the formation of secondary particles is suppressed. Specifically, provided is a composition comprising (A) delamanid particles and (B) a surface stabilizer.
    Type: Application
    Filed: June 11, 2019
    Publication date: August 19, 2021
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Atsuya NAKAMURA, Hiroyuki YAMAZAKI, Masahiro HASEGAWA, Naoki KAMADA
  • Patent number: 9555026
    Abstract: The present invention relates to a solid dispersion comprising cilostazol, and methacrylic acid copolymer S and/or methacrylic acid copolymer L, which is characterized in that cilostazol is retained in an amorphous state in a gastrointestinal tract for a certain period after oral administration.
    Type: Grant
    Filed: February 5, 2014
    Date of Patent: January 31, 2017
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Junichi Kawasaki, Atsuya Nakamura, Naoki Kamada
  • Publication number: 20160000801
    Abstract: This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.
    Type: Application
    Filed: February 28, 2014
    Publication date: January 7, 2016
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Akitsuna AKAGI, Kai SUZUKI, Atsuya NAKAMURA, Toru NISHIBAYASHI
  • Publication number: 20150366859
    Abstract: The present invention relates to a solid dispersion comprising cilostazol, and methacrylic acid copolymer S and/or methacrylic acid copolymer L, which is characterized in that cilostazol is retained in an amorphous state in a gastrointestinal tract for a certain period after oral administration.
    Type: Application
    Filed: February 5, 2014
    Publication date: December 24, 2015
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Junichi KAWASAKI, Atsuya NAKAMURA, Naoki KAMADA